Hemato Oncology Testing Market Outlook:
Hemato Oncology Testing Market size was over USD 4.04 billion in 2025 and is poised to exceed USD 14.21 billion by 2035, witnessing over 13.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of hemato oncology testing is evaluated at USD 4.53 billion.
The continuous advancements in drug discoveries and testing solutions are expected to augment the hemato oncology testing market growth in the coming years. Several companies are focused on developing customized diagnostic solutions to cater to the rising prevalence of cancer cases, including hemato cancer. Precision medicines and personalized diagnostic technologies are emerging as effective solutions compared to traditional counterparts as they are formulated on one’s specific genetic compositions. For instance, in March 2022, Invitae Corporation launched a personalized cancer-detecting (PCM) platform to diagnose minimal or molecular residual disease (MRD) in patients with solid tumors. This PCM platform detects circulating tumor DNA in blood using a set of personalized assays to get reliable results.
